Sagefield Capital’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Sagefield Capital’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,666	Closed	–	–	150
2022 Q2	$0	Hold	2,666	–	–	﹤0.01%	150
2022 Q1	$0	Hold	2,666	–	–	﹤0.01%	158
2021 Q4	$2K	Buy	+2,666	New	+$1.96K	﹤0.01%	158

Other funds holding EUCRW

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Altium Capital Management New York $42M AUM

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sagefield Capital's EUCRW Position: Q3 2022 in Review

Sagefield Capital sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q3 2022, closing a stake of 2,666 shares.

Sagefield Capital first reported a position in EUCRW in Q4 2021 and held it in 3 quarters. The position peaked at $2K in Q4 2021. 24 funds tracked by Wall St. Rank hold EUCRW as of Q3 2022.

Sagefield Capital reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q3 2022 after selling out during the quarter.
Sagefield Capital sold 2,666 Eucrates Biomedical Acquisition Corp. Warrant shares in Q3 2022.
Sagefield Capital first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q4 2021 and held it in 3 quarters.
Sagefield Capital's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $2K in Q4 2021.
24 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q3 2022.

Based on Sagefield Capital's 13F filing for Q3 2022, filed 14 Nov 2022.